MX2021014177A - Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos. - Google Patents

Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos.

Info

Publication number
MX2021014177A
MX2021014177A MX2021014177A MX2021014177A MX2021014177A MX 2021014177 A MX2021014177 A MX 2021014177A MX 2021014177 A MX2021014177 A MX 2021014177A MX 2021014177 A MX2021014177 A MX 2021014177A MX 2021014177 A MX2021014177 A MX 2021014177A
Authority
MX
Mexico
Prior art keywords
kras
inhibitors
mutation
compounds
methods
Prior art date
Application number
MX2021014177A
Other languages
English (en)
Inventor
Michael D Bartberger
Dennis Slamon
Justin A Hilf
Brian M Stoltz
Corey M Reeves
Oliver C Loson
Martina S Mcdermott
Tristin E Rose
Brendan M O''boyle
Neil A O''brien
Original Assignee
California Inst Of Techn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Inst Of Techn filed Critical California Inst Of Techn
Publication of MX2021014177A publication Critical patent/MX2021014177A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a compuestos de la Fórmula I, y sales farmacéuticamente aceptables de los mismos, y métodos para preparar y usar los mismos. Los compuestos de la invención son eficaces para inhibir la proteína KRAS con una mutación G12C y son adecuados para su uso en métodos de tratamiento de cánceres mediados, en su totalidad o en parte, por la mutación KRAS G12C.
MX2021014177A 2019-05-20 2020-05-20 Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos. MX2021014177A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962850289P 2019-05-20 2019-05-20
PCT/US2020/033816 WO2020236940A1 (en) 2019-05-20 2020-05-20 Kras g12c inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
MX2021014177A true MX2021014177A (es) 2022-04-25

Family

ID=73458223

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014177A MX2021014177A (es) 2019-05-20 2020-05-20 Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos.

Country Status (12)

Country Link
US (1) US20220227738A1 (es)
EP (1) EP3972978A4 (es)
JP (1) JP7502337B2 (es)
KR (1) KR20220038289A (es)
CN (1) CN114096544A (es)
AU (1) AU2020279253A1 (es)
BR (1) BR112021023359A2 (es)
CA (1) CA3141604A1 (es)
IL (1) IL288200A (es)
MX (1) MX2021014177A (es)
SG (1) SG11202112790SA (es)
WO (1) WO2020236940A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
US12065430B2 (en) 2018-10-26 2024-08-20 Taiho Pharmaceutical Co., Ltd. Indazole compound or salt thereof
JP2022517222A (ja) 2019-01-10 2022-03-07 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
JP2022548791A (ja) 2019-09-24 2022-11-21 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
CR20220230A (es) 2019-10-28 2022-06-15 Merck Sharp & Dohme Inhibidores de pequeñas moléculas de mutante g12c de kras
CN114630832A (zh) * 2019-11-15 2022-06-14 四川海思科制药有限公司 一种嘧啶并环衍生物及其在医药上的应用
AU2020405170A1 (en) 2019-12-20 2022-06-30 Mirati Therapeutics, Inc. SOS1 inhibitors
TWI770760B (zh) * 2020-01-08 2022-07-11 大陸商蘇州亞盛藥業有限公司 螺環四氫喹唑啉
PE20240493A1 (es) 2020-06-02 2024-03-15 Boehringer Ingelheim Int 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cancer
WO2022040469A1 (en) * 2020-08-19 2022-02-24 The Trustees Of The Stevens Institute Of Technology Spiro compounds as kras inhibitors
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
CN114685502A (zh) 2020-12-25 2022-07-01 由理生物医药（上海）有限公司 作为kras-g12c抑制剂的螺环类化合物
CN114805311A (zh) * 2021-01-21 2022-07-29 苏州亚盛药业有限公司 螺环茚
WO2022240971A2 (en) * 2021-05-11 2022-11-17 1200 Pharma Llc Kras g12d inhibitors and uses thereof
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
AU2022336415A1 (en) 2021-09-01 2024-01-04 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
CA3237274A1 (en) * 2021-11-09 2023-05-19 1200 Pharma Llc Select kras g12c inhibitors and uses thereof
TW202337432A (zh) * 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
CA3240980A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
AU2023218370A1 (en) 2022-02-09 2024-09-19 Quanta Therapeutics, Inc. Kras modulators and uses thereof
WO2024112654A1 (en) 2022-11-21 2024-05-30 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP2209775A1 (en) * 2007-10-09 2010-07-28 UCB Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
CA2926328C (en) 2013-10-10 2022-11-29 Araxes Pharma Llc Substituted quinazolinyl and quinolinyl derivatives and pharmaceutical compositions thereof useful as inhibitors of kras g12c
JO3556B1 (ar) * 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
KR20180005178A (ko) * 2015-04-10 2018-01-15 아락세스 파마 엘엘씨 치환된 퀴나졸린 화합물 및 이의 사용방법
JP7039489B2 (ja) * 2016-05-18 2022-03-22 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
JOP20190186A1 (ar) * 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
US20190134056A1 (en) * 2017-03-10 2019-05-09 The Trustees Of The Stevens Institute Of Technolog K-ras mutations and antagonists
KR20200010306A (ko) * 2017-05-25 2020-01-30 아락세스 파마 엘엘씨 Kras의 공유적 억제제
US10736897B2 (en) 2017-05-25 2020-08-11 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
CA3066939A1 (en) * 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
ES2938987T3 (es) * 2018-06-01 2023-04-18 Amgen Inc Inhibidores de KRAS G12c y métodos de uso de los mismos
EP3746436A4 (en) * 2018-08-16 2022-03-16 F. Hoffmann-La Roche AG CONDENSED CYCLIC COMPOUNDS

Also Published As

Publication number Publication date
IL288200A (en) 2022-01-01
SG11202112790SA (en) 2021-12-30
BR112021023359A2 (pt) 2022-02-01
EP3972978A1 (en) 2022-03-30
EP3972978A4 (en) 2023-04-26
JP7502337B2 (ja) 2024-06-18
CN114096544A (zh) 2022-02-25
AU2020279253A1 (en) 2021-12-16
US20220227738A1 (en) 2022-07-21
CA3141604A1 (en) 2020-11-26
WO2020236940A1 (en) 2020-11-26
KR20220038289A (ko) 2022-03-28
JP2022533398A (ja) 2022-07-22

Similar Documents

Publication Publication Date Title
MX2021014177A (es) Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos.
MX2020012261A (es) Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
SA522432955B1 (ar) Kras g12c مثبطات
EA201890318A1 (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
MX2020012731A (es) Inhibidores de kras g12c y metodos para su uso.
MX2021005700A (es) Inhibidores de kras g12c y metodos de uso de los mismos.
MX2021002804A (es) Terapias de combinacion.
MX2020010836A (es) Inhibidores de kras g12c y métodos para su uso.
ZA202202559B (en) Kras g12c inhibitors and methods of using the same
MX2020011582A (es) Inhibidores de kras g12c y metodos para su uso.
MX2020012204A (es) Inhibidores de kras g12c para tratar el cáncer.
SA519401541B1 (ar) [1، 5-a] مركبات بيرازولو كيناز ret بيريدين بها استبدال كمثبطات
MX2020011907A (es) Inhibidores de kras g12c para el tratamiento de cancer.
MX2020002502A (es) Inhibidores de kras g12c y metodos para utilizarlos.
MY196830A (en) Kras g12c inhibitors and methods of using the same
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
EA201792214A1 (ru) Соединения замещенного хиназолина
EA201991884A2 (ru) Ингибиторы g12c kras
MX2017002986A (es) Compuestos de piperidina sustituidos.
MX2022005298A (es) Compuestos intermediarios de sintesis de inhibidores de a2a.
MX2024008551A (es) Terapias de combinacion.
MY192861A (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
WO2022240971A3 (en) Kras g12d inhibitors and uses thereof
MX2021012499A (es) Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos.